Zvelt Therapeutics

Zvelt Therapeutics is a private U.S. preclinical biotech company developing adipose-targeted gene therapies for rare metabolic diseases. Its lead effort is an rAAV-based leptin gene therapy for lipodystrophy designed to direct expression to fat tissue while minimizing off-target liver expression. The company appears to center its strategy on an engineered AAV serotype, Rec2, combined with a dual-cassette vector approach intended to improve tissue specificity and safety. Publicly visible information indicates Zvelt has advanced its program through NIH/SBIR-funded preclinical development and is working toward IND-enabling studies. The company is best characterized as an early-stage gene therapy startup focused on adipose biology and rare endocrine-metabolic disease.